We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis.
- Authors
Rosen, M. J.; Minar, P.; Vinks, A. A.
- Abstract
Background Acute severe ulcerative colitis ( ASUC), the most aggressive presentation of ulcerative colitis ( UC), occurs in 15% of adults and children with UC. First line therapy with intravenous corticosteroids is ineffective in half of adults and one-third of children. Therapeutic monoclonal antibodies against TNF (anti- TNF therapy) are emerging as a common treatment for ASUC due to their similar efficacy to calcineurin inhibitors and more favourable adverse effect profile. Aim To comprehensively review the evidence for anti- TNF therapy for ASUC in children and adults with regard to outcomes and pharmacokinetics. Methods PubMed and recent conference proceedings were searched using the terms 'ulcerative colitis', 'acute severe ulcerative colitis', 'anti- TNF', 'pharmacokinetics' and the generic names of specific anti- TNF agents. Results Outcomes after anti- TNF therapy for ASUC remain suboptimal with about one half of children and adults undergoing colectomy. While several randomised controlled trials have demonstrated the efficacy of anti- TNF therapy for ambulatory patients with moderate to severely active UC, patients in these studies were less ill than those with ASUC. Patients with ASUC may exhibit more rapid clearance of anti- TNF biologics due to pharmacokinetic mechanisms influenced by disease severity. Conclusions Conventional weight-based dosing effective in patients with moderately to severely active UC, may not be equally effective in those with acute severe ulcerative colitis. Personalised anti- TNF dosing strategies, which integrate patient factors and early measures of pharmacokinetics and response, hold promise for ensuring sustained drug exposure and maximising early mucosal healing in patients with acute severe ulcerative colitis.
- Subjects
PHARMACOKINETICS; DRUG dosage; IMMUNOGLOBULINS; TUMOR necrosis factors; ULCERATIVE colitis; COLITIS treatment; DRUG efficacy
- Publication
Alimentary Pharmacology & Therapeutics, 2015, Vol 41, Issue 11, p1094
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.13175